Many previously unexplained life-threatening ventricular arrhythmias and sudden cardiac
deaths (SCDs) in young individuals are now recognized to be genetic in nature and are …

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left
ventricular hypertrophy and is classically caused by pathogenic or likely pathogenic variants …

With the development and advancement of next-generation sequencing (NGS), genetic
analysis is becoming more accessible. High-throughput genetic studies using NGS have …

We sought to establish a large animal model of inherited hypertrophic cardiomyopathy
(HCM) with sufficient disease severity and early penetrance for identification of novel …

Hypertrophic cardiomyopathy (HCM) is a global and relatively common cause of patient
morbidity and mortality and is among the first reported monogenic cardiac diseases. For 30 …

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder,
affecting 1 in 500 people in the general population. Although characterized by asymmetric …

Aims Current guidelines recommend initiating family screening for hypertrophic
cardiomyopathy (HCM) after age 10 or 12 years unless early screening criteria are met. The …

All muscle contraction occurs due to the cyclical interaction between sarcomeric thin and
thick filament proteins within the myocyte. The thin filament consists of the proteins actin …

Background: Pathogenic variants in MYBPC3, encoding cardiac MyBP-C (myosin binding
protein C), are the most common cause of familial hypertrophic cardiomyopathy. A large …

This scientific statement from the American Heart Association focuses on treatment
strategies and modalities for cardiomyopathy (heart muscle disease) in children and serves …